---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-106315"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2021-08-16T23:59:59+00:00"
generated_at: "2026-06-29T10:03:52.023145+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acurx Q2 2021 net loss $4.0M ($0.57/diluted share); IPO raised $17.25M gross

## Summary
- Net loss of $4.0M for Q2 2021 vs $0.9M loss in Q2 2020; R&D expenses down to $0.1M from $0.4M.
- Cash balance $17.1M as of June 30, 2021, following June IPO gross proceeds of $17.25M including overallotment.
- Health Holland awarded ~$500K grant to Leiden University to study DNA pol IIIC inhibitors in collaboration with Acurx.
- Filed provisional patent for ibezapolstat to treat C. difficile infection with reduced recurrence and improved microbiome health.
- SG&A expenses rose to $3.9M in Q2 2021 from $0.5M in Q2 2020, driven by stock-based compensation and professional fees.

## SEC filing metadata
- accession: 0001104659-21-106315
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2021-08-16T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465921106315/0001104659-21-106315-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465921106315/tm2125031d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-106315
- JSON: https://secwatch.observer/filing/0001104659-21-106315.json
- Plain text: https://secwatch.observer/filing/0001104659-21-106315.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.